We’re looking forward to the mRNA-Based Therapeutics Summit in Boston later this month! Stop by Booth 17 to learn about ELEGEN's fast next-gen DNA production: long, NGS-verified, clonal-quality DNA with industry-leading complexity, ready for immediate input into mRNA-based workflows to accelerate therapeutics development. #EnfiniaDNA #nextgenDNA #mRNAvaccines #mRNAtherapeutics
ELEGEN’s Post
More Relevant Posts
-
🚀 Explore the Special Session: "SPS-04 TB therapeutics: Reflecting on the past and charting the way forward" at 15:00 CET in Room 242A. Join the discussion on groundbreaking approaches to TB treatment. Your engagement contributes to the ongoing quest for innovative therapeutics 🙌 #TB #Research #UnionConf2023
To view or add a comment, sign in
-
-
Ensure your #mRNA vaccine & therapeutic products analytical development success! 🚀 We hope to see you at the mRNA-Based Therapeutics Summit in Boston (July 29-31). Find out how Intertek experts can support your mRNA therapeutics development from early-stage characterization to late-stage development and commercialization! Please stop by our booth or contact us to schedule a meeting: Diogo Rodrigues and Mairita Ntoulovi. 🌍 Event: 4th Annual mRNA-Based Therapeutics Summit 📅 When: July 29-31, 2024 📍 Where: Boston, MA #mRNATherapeutics #mRNATherapeuticsSummit #mRNABasedTherapeuticsSummit
To view or add a comment, sign in
-
-
I'm looking forward to meeting attendees at the 5th Inflammasome Therapeutics Summit in Boston next week. It's a fascinating time for inflammasome therapeutics, with NLRP3 inhibitors progressing in the Clinic and other members of the inflammasome family gaining traction in early discovery. Please let me know if you're attending and would like to learn more about what working with Sygnature Discovery can offer. https://lnkd.in/eeXBZGxT #inflammasome #drugdiscovery #drugdevelopment #NLRP3 #inflammation #autoimmunediseases
To view or add a comment, sign in
-
Precision Medicine | Business Development | Customer Advocacy | Marketing Strategy | Consulting | Pharma & Biotech |
🔔 Our new case study in collaboration with our partner MacroGenics, Inc. is now out!! This is a excellent example of how #GenedataProfiler empowers scientific domain experts to unlock value from #clinicaltrial data to advance #precisionmedicine! You can access the material by following the link below 👇🏽 Reach out if you want to discuss further!
Looking to maximize the value unlocked from R&D data to inform the clinical development of #immunotherapy? Read this case study to discover how MacroGenics, Inc. benefits from the support of Genedata to derive biological insights from complex #data to improve clinical trial success and healthcare outcomes of their antibody-based therapeutics. 👉https://buff.ly/4d3fSep #GenedataProfiler #Biomarkers #DataIntegration
To view or add a comment, sign in
-
-
Come join us on April 17th at 9am at the Colonnade Hotel in Boston, MA at the 4th Fc Mediated Function Summit and learn about how to incorporate our platform in order to develop safer more efficacious monoclonal therapeutics. #mAbtherapeutics #Fceffectorfuntion #Fcmediatedfunctionsummit
To view or add a comment, sign in
-
-
Looking to maximize the value unlocked from R&D data to inform the clinical development of #immunotherapy? Read this case study to discover how MacroGenics, Inc. benefits from the support of Genedata to derive biological insights from complex #data to improve clinical trial success and healthcare outcomes of their antibody-based therapeutics. 👉https://buff.ly/4d3fSep #GenedataProfiler #Biomarkers #DataIntegration
To view or add a comment, sign in
-
-
Your one-stop-shop for many things mRNA🤝 ...Don't just take our word for it - check out what some of our expert speakers have to say about the 4th mRNA-Based Therapeutics Summit this July! Get your copy of the three-day program here, jam-packed with four tracks' worth of mRNA content: https://ter.li/s9qfa7 #mRNA #mRNATherapeutics #mRNAVaccines #RNA #WorldRNA #mRNASummit
To view or add a comment, sign in
-
-
Looking to unlock the full potential of your exploratory #data to advance your #clinicaltrials and maximize the benefit of your treatments in development? Read this case study to learn how our trusted partner, MacroGenics achieved this with Genedata Profiler. #Immunooncology #DrugDevelopment #PathToPrecision
Looking to maximize the value unlocked from R&D data to inform the clinical development of #immunotherapy? Read this case study to discover how MacroGenics, Inc. benefits from the support of Genedata to derive biological insights from complex #data to improve clinical trial success and healthcare outcomes of their antibody-based therapeutics. 👉https://buff.ly/4d3fSep #GenedataProfiler #Biomarkers #DataIntegration
To view or add a comment, sign in
-
-
Two's company - three's a crowd? Given the great success of bispecific antibodies in recent years, you'd be forgiven for thinking two targets was adequate for antibody drug development. But adding a third can help to engage tumor cells, immune cells and other parts of the immune system to even further enhance anti-tumor activity. Here at Hanson Wade Intelligence, recent analysis by our senior analyst Callum Angus has highlighted trispecific antibodies as one of the fastest-growing modalities in the whole of the life science field. There is a particular focus on solid tumor indications, which tend to be more immunologically "cold" and therefore standing to benefit most from this extra immune stimulation. This energy is reflected in recent business events, with not just Ipsen (below), but big-hitters Merck and Gilead Sciences making billion-dollar deals in this area, throwing considerable support and faith to what is already a fast-growing movement. If you would like to learn more about how we can help our clients understand more about the latest emerging technologies in biopharma, and how this information can be used to better inform their strategic decisions, please reach out to us at Hanson Wade Intelligence here: [email protected] or visit our website: https://lnkd.in/e9yRCP4U #bispecific #trispecific #drugdevelopment #lifescience #oncology #antibody #pharma #biotech https://lnkd.in/eQnbcYJt
Ipsen returns to Marengo Therapeutics for new trispecific deal
https://endpts.com
To view or add a comment, sign in
-
Fascinating to see the moves being made in the trispecific antibody space! #trispecific #bispecific #antibody #antibodytherapy #lifesciences #marketresearch #consulting #ipsen #gilead #merck
Two's company - three's a crowd? Given the great success of bispecific antibodies in recent years, you'd be forgiven for thinking two targets was adequate for antibody drug development. But adding a third can help to engage tumor cells, immune cells and other parts of the immune system to even further enhance anti-tumor activity. Here at Hanson Wade Intelligence, recent analysis by our senior analyst Callum Angus has highlighted trispecific antibodies as one of the fastest-growing modalities in the whole of the life science field. There is a particular focus on solid tumor indications, which tend to be more immunologically "cold" and therefore standing to benefit most from this extra immune stimulation. This energy is reflected in recent business events, with not just Ipsen (below), but big-hitters Merck and Gilead Sciences making billion-dollar deals in this area, throwing considerable support and faith to what is already a fast-growing movement. If you would like to learn more about how we can help our clients understand more about the latest emerging technologies in biopharma, and how this information can be used to better inform their strategic decisions, please reach out to us at Hanson Wade Intelligence here: [email protected] or visit our website: https://lnkd.in/e9yRCP4U #bispecific #trispecific #drugdevelopment #lifescience #oncology #antibody #pharma #biotech https://lnkd.in/eQnbcYJt
Ipsen returns to Marengo Therapeutics for new trispecific deal
https://endpts.com
To view or add a comment, sign in